205 related articles for article (PubMed ID: 19840522)
1. Critical signaling pathways in bone sarcoma: candidates for therapeutic interventions.
Geryk-Hall M; Hughes DP
Curr Oncol Rep; 2009 Nov; 11(6):446-53. PubMed ID: 19840522
[TBL] [Abstract][Full Text] [Related]
2. Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas.
Albarrán V; Villamayor ML; Chamorro J; Rosero DI; Pozas J; San Román M; Calvo JC; Pérez de Aguado P; Moreno J; Guerrero P; González C; García de Quevedo C; Álvarez-Ballesteros P; Vaz MÁ
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430263
[TBL] [Abstract][Full Text] [Related]
3. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.
Kurmasheva RT; Dudkin L; Billups C; Debelenko LV; Morton CL; Houghton PJ
Cancer Res; 2009 Oct; 69(19):7662-71. PubMed ID: 19789339
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
[TBL] [Abstract][Full Text] [Related]
5. IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.
Lamhamedi-Cherradi SE; Menegaz BA; Ramamoorthy V; Vishwamitra D; Wang Y; Maywald RL; Buford AS; Fokt I; Skora S; Wang J; Naing A; Lazar AJ; Rohren EM; Daw NC; Subbiah V; Benjamin RS; Ratan R; Priebe W; Mikos AG; Amin HM; Ludwig JA
J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27576731
[TBL] [Abstract][Full Text] [Related]
6. New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?
Danieau G; Morice S; Rédini F; Verrecchia F; Royer BB
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370265
[TBL] [Abstract][Full Text] [Related]
7. Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy.
Rivera-Valentin RK; Zhu L; Hughes DP
Paediatr Drugs; 2015 Aug; 17(4):257-71. PubMed ID: 26002157
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas.
Anderson JL; Park A; Akiyama R; Tap WD; Denny CT; Federman N
PLoS One; 2015; 10(9):e0133610. PubMed ID: 26402468
[TBL] [Abstract][Full Text] [Related]
9. Novel agents in development for pediatric sarcomas.
Hughes DP
Curr Opin Oncol; 2009 Jul; 21(4):332-7. PubMed ID: 19444103
[TBL] [Abstract][Full Text] [Related]
10. Use of chemotherapy for patients with bone and soft-tissue sarcomas.
Wesolowski R; Budd GT
Cleve Clin J Med; 2010 Mar; 77 Suppl 1():S23-6. PubMed ID: 20179184
[TBL] [Abstract][Full Text] [Related]
11. Hedgehog pathway in sarcoma: from preclinical mechanism to clinical application.
Banaszek N; Kurpiewska D; Kozak K; Rutkowski P; Sobczuk P
J Cancer Res Clin Oncol; 2023 Dec; 149(19):17635-17649. PubMed ID: 37815662
[TBL] [Abstract][Full Text] [Related]
12. Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas.
Sethi TK; Keedy VL
Curr Treat Options Oncol; 2016 Feb; 17(2):11. PubMed ID: 26931561
[TBL] [Abstract][Full Text] [Related]
13. NVP-BEZ235 as a new therapeutic option for sarcomas.
Manara MC; Nicoletti G; Zambelli D; Ventura S; Guerzoni C; Landuzzi L; Lollini PL; Maira SM; García-Echeverría C; Mercuri M; Picci P; Scotlandi K
Clin Cancer Res; 2010 Jan; 16(2):530-40. PubMed ID: 20068094
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.
Beltran PJ; Chung YA; Moody G; Mitchell P; Cajulis E; Vonderfecht S; Kendall R; Radinsky R; Calzone FJ
J Pharmacol Exp Ther; 2011 Jun; 337(3):644-54. PubMed ID: 21385891
[TBL] [Abstract][Full Text] [Related]
15. IGF-1R/MDM2 relationship confers enhanced sensitivity to RITA in Ewing sarcoma cells.
Di Conza G; Buttarelli M; Monti O; Pellegrino M; Mancini F; Pontecorvi A; Scotlandi K; Moretti F
Mol Cancer Ther; 2012 Jun; 11(6):1247-56. PubMed ID: 22461661
[TBL] [Abstract][Full Text] [Related]
16. The value of adjuvant chemotherapy in the management of sarcomas in children.
Donaldson SS
Cancer; 1985 May; 55(9 Suppl):2184-97. PubMed ID: 3884137
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapies in bone sarcomas.
Scotlandi K; Picci P; Kovar H
Curr Cancer Drug Targets; 2009 Nov; 9(7):843-53. PubMed ID: 20025572
[TBL] [Abstract][Full Text] [Related]
18. Cabozantinib as an emerging treatment for sarcoma.
Schöffski P; Blay JY; Ray-Coquard I
Curr Opin Oncol; 2020 Jul; 32(4):321-331. PubMed ID: 32541320
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.
Scotlandi K; Manara MC; Nicoletti G; Lollini PL; Lukas S; Benini S; Croci S; Perdichizzi S; Zambelli D; Serra M; García-Echeverría C; Hofmann F; Picci P
Cancer Res; 2005 May; 65(9):3868-76. PubMed ID: 15867386
[TBL] [Abstract][Full Text] [Related]
20. New molecular insights into osteosarcoma targeted therapy.
Yang J; Zhang W
Curr Opin Oncol; 2013 Jul; 25(4):398-406. PubMed ID: 23666471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
